Kilkenny-based CF Pharma Medical has reported a significant regulatory milestone for its wound-care portfolio, with its Effigerm Wound Care product achieving Class IIb certification under the European Union’s Medical Device Regulation (MDR). The development highlights the growing capabilities of Ireland’s medical-device manufacturing sector and the importance of regulatory expertise in bringing healthcare products to international markets.

The announcement, published by Kilkenny People on 14 November 2026, identifies Effigerm Wound Care as a product designed for wound cleansing, debridement and irrigation. It is available in liquid and hydrogel formulations, with the company reporting that the certification follows technical development, clinical evaluation and regulatory assessment.

The classification is commercially relevant because the MDR establishes different conformity assessment requirements according to a medical device’s risk classification. The Health Products Regulatory Authority (HPRA) explains that classification determines the applicable safety and performance requirements and the route a manufacturer must follow before a device can be CE marked and placed on the EU market. The specific Effigerm Class IIb certificate was not independently available for review, so the classification remains attributed to the company’s announcement.

CF Pharma Medical’s manufacturing base gives the development a wider Irish industry dimension. According to the company’s official profile, the Irish-owned business was founded in 2014 and operates from a purpose-built 25,000 sq. ft facility in Kilkenny. Its capabilities span research and development, manufacturing, regulatory support and customer service, with ISO 13485 and HACCP accreditations.

Managing Director Caroline Fogarty said the certification reflects the work invested by the team in quality systems, technical documentation, clinical evaluation and regulatory compliance. The company says the milestone provides a stronger platform for expanding existing partnerships and developing new commercial opportunities across Europe and other international healthcare markets.

The announcement also reinforces the importance of Ireland’s specialist manufacturers within the wider healthcare supply chain. Businesses combining formulation expertise, regulated production and technical support can offer valuable capabilities to healthcare partners seeking products that meet demanding market requirements.

For the sector, the lesson is direct: medical-device innovation needs manufacturing and regulatory strength behind it. CF Pharma Medical’s reported achievement puts Kilkenny’s healthcare manufacturing expertise in focus and signals the commercial potential of continued investment in Irish-developed wound-care solutions.